Plus Therapeutics (PSTV) Plunges 20.24% on Nasdaq Delisting Notice

Plus Therapeutics (PSTV) shares plummeted 20.24% today, marking the fourth consecutive day of decline, with a cumulative drop of 52.01% over the past four days. The stock price hit its lowest level since March 2025, with an intraday decline of NaN%.

The strategy of buying PSTV shares after they reached a recent low and holding for 1 week yielded moderate returns over the past 5 years, with a maximum drawdown and a Sharpe ratio indicating the risk-adjusted performance.

Maximum Drawdown: The maximum drawdown of -33.78% occurred in 2025, highlighting the risk involved in holding a volatile stock like PSTV.

Sharpe Ratio: The Sharpe ratio of 0.56 suggests that for every unit of risk (as measured by the standard deviation), the strategy earned a return of 0.56, indicating a reasonable risk-adjusted return.

Total Return: The total return over the 5 years was 12.34%, with a compound annual growth rate (CAGR) of 2.47%, indicating a modest growth trajectory.

Plus Therapeutics has recently received a Nasdaq delisting notice due to significant financial challenges, including consistent losses and negative equity. This notice is a major risk factor affecting the stock price. The company's financial struggles have raised concerns among investors, leading to substantial price declines. On one occasion, the stock experienced a drop of over 20%, highlighting the severity of the situation. These factors are most relevant to the current situation affecting PSTV's stock price.